Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (April 21st Preview)
-
Eli Lilly in vivo CAR-T expansion via Kelonia acquisition
Eli Lilly agreed to acquire Kelonia Therapeutics in a deal worth up to $7 billion, expanding the company’s in vivo CAR-T ambitions for multiple myeloma and beyond. Lilly will pay $3.25 billion upfront, with additional milestone payments tied to clinical, regulatory and commercial outcomes, with the transaction expected to close in the second half of 2026.
-
Updated clinical signal in alopecia areata extension study
Nektar Therapeutics disclosed additional hair-regrowth data from a 16-week extension of its Phase IIb REZOLVE-AA study of rezpegaldesleukin (rezpeg), highlighting deeper responses among late responders in severe alopecia areata. The company said rezpeg drove additional regrowth during the extension period.
-
Whole-genome ctDNA MRD readout streamlines risk stratification in lung cancer
At AACR, researchers reported clinical value for tumor-informed MRD detection using whole-genome sequencing paired with Ultima Genomics duplex sequencing in TRACERx. The approach, using paired plus-minus sequencing (ppmSeq), enabled intermediate risk group identification without bespoke assays, with ctDNA analyses showing concordance with prior datasets and relapse-free survival prediction.
-
NEOPRISM-CRC bowel cancer trial reports zero relapses after short immunotherapy lead-in
A clinical trial led by University College London (UCL) and UCL Hospitals (UCLH) reported follow-up results from NEOPRISM-CRC, testing a short course of immunotherapy prior to surgery for a subset of bowel cancer patients. The update described zero relapses in the trial results presented, drawing attention to how preoperative immunotherapy may reshape surgical sequencing.
-
In vitro gene-editing map pinpoints HIV host factors in primary CD4+ T cells
Gladstone Institutes and UCSF published a genome-wide CRISPR screen mapping human genes that either promote or restrict HIV infection in primary CD4+ T cells. Using optimized infection conditions to raise infection rates to about 70%, the team ran CRISPRa and knockout screens and reported a first-of-its-kind host–virus blueprint for immune cells that are the virus’s actual in-body target.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.